Neumora Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2022 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Neumora Therapeutics, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2022 to 2023.
- Neumora Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$58.6M, a 52% decline year-over-year.
- Neumora Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$236M, a 80% decline from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)